TABLE 2.
In vitro antiviral efficacy of AG7088 in the presence of AAG or mucina
| Treatmentb | EC50 (μM)c | EC90 (μM)c | CC50 (μM) | Therapeutic indexd |
|---|---|---|---|---|
| No AAG | 0.009, 0.033 | 0.031, 0.048 | >1 | >48 |
| AAG | 0.043 ± 0.020 | 0.108 ± 0.038 | >1 | >23 |
| No mucin | 0.059 ± 0.019 | 0.086, 0.234 | >10 | >169 |
| Mucin | 0.030 ± 0.019 | 0.074 ± 0.033 | >10 | >333 |
a
Antiviral efficacy was determined by measuring XTT dye reduction following 2 or 3 days of infection of H1-HeLa cells with HRV 14 as described in Materials and Methods.
b
Experiments were conducted in the presence or absence of AAG or mucin (1 mg/ml), both resuspended in medium containing 10% fetal bovine serum.
c
Results represent the means ± standard deviations (three or four experiments) or individual values (one or two experiments).
d
Therapeutic index = CC50/EC50.